Microcurrent Electrical Nerve Stimulation Improves Blood Glucose Control in Type 2 Diabetes
Biochemical for Microarray Testing – Cluster Analysis
Experimentation of the Application of Microcurrent Electrical Nerve Stimulation on Animal Models with Type 2 Diabetes.
Our study involved administering a microcurrent electrical nerve stimulation (MENS) on STZ-induced diabetic animal models.
Results of fasting blood glucose and OGTT, among other indices, demonstrated the effect of MENS on modulating blood sugar levels and other diabetes-related symptoms.
Completed Feasibility Study (Simple Size, 80 people) January 2014 – December 2015
Medical Centers Conducting Clinical Trial
History of Research and Development of MENS for Type 2 Diabetes Indications
|Mar 2013||Obtained TFDA’s medical device license: 003997 (Class II, blood circulation, pain relief, and relaxation functions)|
|Jul 2013||Completed a study on patients with type 2 diabetes from Luodong Neng-Chun Diabetes Clinic|
|Jan 2014 - Dec 2015||Conducted a single-blind, randomized study at Saint Mary's Hospital Luodong on the effects of "Dragon Waves Resonant Home Care Electronic Nerve Stimulator” (DW1330) on improving blood glucose control in patients with type 2 diabetes (sample size of 80)|
|May 2015 - Jun 2015||Completed the analysis of animal models with type 2 diabetes (National Taiwan Sport University), genomic analysis (National Chiao Tung University), proteomics analysis (National Yang Ming University)|
|Apr 2017 - Dec 2018||NTUH and NCKUH, in collaboration with two other medical facilities, has begun a prospective, double-blind, randomized, placebo-controlled trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to improve blood glucose control in patients with type 2 diabetes|
|Dec 2019||Expect to obtain TFDA’s medical device license (Intended use: an adjuvant treatment for T2DM patients who take oral medications)|